Loading organizations...
§ Private Profile · Washington, DC, USA
Prestwick Pharmaceuticals is a technology company.
Prestwick Pharmaceuticals develops small molecule drugs targeting chronic central nervous system diseases. The company focuses on neurological conditions such as restless legs syndrome and schizophrenia, advancing its pipeline of therapeutic candidates. Its approach emphasizes rigorous compound development to modulate specific pathways, aiming for improved patient outcomes in these challenging disorders.
Founded in 2002, Prestwick Pharmaceuticals emerged from a recognition of unmet medical needs in CNS disorders. Its core insight centered on targeted small molecule therapies offering advancements where existing treatments proved insufficient. This premise guided early research and development by a team dedicated to innovative neuropharmacology.
Prestwick Pharmaceuticals' work benefits patients globally suffering from debilitating chronic CNS conditions. The company's vision is to advance pharmacological treatment for these diseases by bringing effective, well-tolerated medicines to market. This commitment alleviates suffering and improves quality of life through scientific discovery.
Prestwick Pharmaceuticals has raised $132.0M across 4 funding rounds.
Prestwick Pharmaceuticals has raised $132.0M in total across 4 funding rounds.
Prestwick Pharmaceuticals has raised $132.0M in total across 4 funding rounds.
Prestwick Pharmaceuticals's investors include Sofinnova Investments.
Prestwick Pharmaceuticals has raised $132.0M across 4 funding rounds. Most recently, it raised $20.0M Series U in August 2007.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2007 | $20M Series U | — | Sofinnova Investments | Announced |
| Oct 1, 2006 | $60M Series C | — | Sofinnova Investments | Announced |
| Dec 1, 2004 | $37M Series B | — | Sofinnova Investments | Announced |
| Jun 1, 2003 | $15M Series A | — | Sofinnova Investments | Announced |
Prestwick Pharmaceuticals, Inc. is a product-focused specialty pharmaceutical company specializing in the development and commercialization of small molecule drugs with high commercial potential, particularly targeting serious central nervous system (CNS) disorders as a precision-neuroscience firm.[1][3] It operates in drug manufacturing, research, and pharmaceuticals, based in Washington, D.C., serving patients with CNS conditions through innovative treatments.[2]
The company addresses unmet needs in CNS therapeutics by advancing precision medicines, though specific products, customer segments, or recent growth metrics are not detailed in available data.[1][3]
Limited public information exists on Prestwick Pharmaceuticals' founding year, founders, or early milestones, with no records of key partners or pivotal traction events identified.[1][2][3] It is described as a specialty pharmaceutical entity focused on small molecule drugs, suggesting origins in biotech R&D, but backstory details like idea emergence or initial progress remain unavailable in current sources.[3]
No specifics on developer experience, pricing, community, or unique tech edges are available.[1][2][3]
Prestwick rides the trend of precision medicine in neuroscience, capitalizing on growing demand for CNS-targeted small molecule therapies amid rising neurological disorder prevalence.[1] Timing aligns with biotech advances in CNS drug pipelines, though market forces like regulatory hurdles and funding for specialty pharma favor nimble players like Prestwick.[3] Its influence on the ecosystem appears niche, contributing to CNS innovation without noted broader impacts.[1][2]
Prestwick's path forward likely involves advancing CNS pipelines, potentially expanding commercialization if small molecule programs gain traction, shaped by biotech funding cycles and CNS market growth.[1][3] Evolving regulatory approvals and partnerships could amplify its role, but sparse data limits precise forecasting—watch for pipeline updates to gauge momentum.[1] This positions it as a specialized contender in precision pharma, echoing its core mission in high-potential CNS therapeutics.[3]